AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02411955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
Study NCT02411955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac®
Description: Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
Study NCT02411955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
Study NCT01206569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting tacrolimus (Advagraf, Astellas Pharma)
Description: Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
Study NCT03985176 — intervention group
Intervention type: DEVICE
Intervention: ROTEM
Description: ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
Study NCT03985176 — intervention group
Intervention type: PROCEDURE
Intervention: EEG
Description: Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
Study NCT03985176 — intervention group
Intervention type: PROCEDURE
Intervention: bilateral compression ultrasound of the lower extremity veins
Description: to exclude asymptomatic deep venous thrombosis once over days 3 to 7
Study NCT00619463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
Study NCT00619463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
Study NCT04795349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted breast biopsy
Description: In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
Study NCT00218959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).
Study NCT00218959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Study NCT01225341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study NCT00104689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00104689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02344732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homatropine 2% eye drops thrice daily
Study NCT02344732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Study NCT01225341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study NCT01225341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic normal saline
Description: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study NCT01225341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline
Description: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study NCT04271267 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT01830530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
Study NCT01830530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
Study NCT01830530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two tablets daily in the morning
Study NCT01994083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01994083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Description: Administered orally
Study NCT02386774 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
Description: used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
Study NCT02386774 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)
Description: used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine
Study NCT01383486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium ER (BAYH6689)
Description: Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
Study NCT01383486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil
Description: Commercially available Advil; oral caplet upon incidence of pain
Study NCT03666728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200 mg iv every 3 weeks
Study NCT03666728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: BP102 was administered 15 mg/kg iv every 3 weeks
Study NCT03592953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game simulation training sessions
Description: Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios.
Study NCT04414891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).
Study NCT04414891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).
Study NCT06416826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibroacoustic Therapy System - VTS 1000
Description: Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
Study NCT04277390 — intervention group
Intervention type: OTHER
Intervention: clinical intervention for microbial analysis and MIR155 as biomarker
Description: Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
Study NCT01449643 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Threshold
Study NCT03347578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
Study NCT02125604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: capsules administered according to the prevailing product label
Study NCT03133962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adult patients who are candidates for a CAP or long-term central catheter placement
Description: Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
Study NCT03171428 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
Study NCT02324127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hsp90
Description: Detect plasma Hsp90α concentration of lung cancer patients
Study NCT02364401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Catheter ablation for atrial fibrillation
Study NCT02364401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Catheter ablation for atrial fibrillation
Study NCT01514786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Web
Description: The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
Study NCT03276520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ethyl glucuronide
Description: alcohol urine screening with ethyl glucuronide
Study NCT03276520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: alcohol urine screening with ethanol
Study NCT00434239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Ancestim
Description: Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
Study NCT04118452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based early childhood developmental care coordination
Description: The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
Study NCT00594945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 1 Dose
Study NCT04195191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANM
Description: communication intervention
Study NCT04195191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: regular assistance in community pharmacies
Study NCT00745849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40mg by mouth twice daily
Study NCT00745849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02656680 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
Study NCT02656680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
Study NCT02656680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Closed Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
Study NCT01143389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
Study NCT01143389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin.
Study NCT03502109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review with follow-up
Description: Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
Study NCT01955304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
Study NCT03120273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Injection
Description: 15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
Study NCT03120273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole Injection
Description: 30 mg q12h for 5 days.
Study NCT02386774 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: microangiography
Description: realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
Study NCT00644592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate capsule daily for 4 weeks
Description: Placebo capsule daily for 4 weeks
Study NCT00644592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 160 mg/day orally for 4 weeks
Study NCT00261040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Surgery
Description: In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
Study NCT00261040 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Surgery
Description: The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
Study NCT01695746 — intervention group
Intervention type: DRUG
Intervention: C.E.R.A.
Description: Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
Study NCT03847207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0030310
Description: Solution for Subcutaneous injection
Study NCT03847207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 600 μg for subcutaneous injection
Study NCT03847207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo Solution
Study NCT01262898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (5 mg tablet)
Description: 5 mg tablet
Study NCT02641041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: single or multiple dose
Study NCT02641041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or multiple dose
Study NCT02632942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAQ criteria
Description: Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. >30% in diameter and associated with stenosis at site of origin.
Study NCT02632942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Recommendation
Description: Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
Study NCT00439634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1625
Description: oral administration
Study NCT04170933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic recanalization
Description: 1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support.
Study NCT06398691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nazal CPAP
Study NCT06398691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidified high-flow air support with nasal cannula
Study NCT00005849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study NCT00005849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02605239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching teeth
Description: bleaching teeth with carbamide peroxide 10% for 3 weeks
Study NCT01370915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
Study NCT01370915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin complex (placebo)
Description: Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
Study NCT03344393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: intravenous ketamine infusion intraoperatively
Study NCT03344393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: intravenous normal saline infusion intraoperatively
Study NCT01860404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: The three BCAA's will be combined together and dissolved in a flavored solution.